Impact of Fusobacterium nucleatum in the treatment of cancer, including radiotherapy and its future potential in esophageal cancer.

IF 1.9 4区医学 Q2 BIOLOGY

Journal of Radiation Research Pub Date : 2024-12-16 DOI:10.1093/jrr/rrae061

Manato Ohsawa, Hiromi Nishi, Manabu Emi, Toru Yoshikawa, Yoichi Hamai, Yuta Ibuki, Tomoaki Kurokawa, Ryosuke Hirohata, Nao Kitasaki, Miki Kawada-Matsuo, Hitoshi Komatsuzawa, Hiroyuki Kawaguchi, Morihito Okada

{"title":"Impact of Fusobacterium nucleatum in the treatment of cancer, including radiotherapy and its future potential in esophageal cancer.","authors":"Manato Ohsawa, Hiromi Nishi, Manabu Emi, Toru Yoshikawa, Yoichi Hamai, Yuta Ibuki, Tomoaki Kurokawa, Ryosuke Hirohata, Nao Kitasaki, Miki Kawada-Matsuo, Hitoshi Komatsuzawa, Hiroyuki Kawaguchi, Morihito Okada","doi":"10.1093/jrr/rrae061","DOIUrl":null,"url":null,"abstract":"<p><p>Despite advances in multimodality therapy, including surgery, chemotherapy, radiation therapy and chemoradiation, the fatality rate for esophageal cancer remains high. Specifically, Fusobacterium nucleatum, due to its aggregation capacity, has shown a tendency to form biofilms. The biofilm-forming capabilities of microbial communities are of utmost importance in the context of cancer treatment, as they have been shown to drive significant losses in the efficaciousness of various cancer treatments. Therefore, elucidating the dynamics of F. nucleatum will be important for the development of effective treatments for esophageal cancer. Therefore, this review summarizes the current knowledge of F. nucleatum, its involvement in cancer and its impact on chemotherapy and radiation therapy. In conclusion, further research on the role of F. nucleatum is essential for the continued advancement of the treatment of esophageal cancer and patient care.</p>","PeriodicalId":16922,"journal":{"name":"Journal of Radiation Research","volume":"65 Supplement_1","pages":"i126-i134"},"PeriodicalIF":1.9000,"publicationDate":"2024-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11647932/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Radiation Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/jrr/rrae061","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"BIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Despite advances in multimodality therapy, including surgery, chemotherapy, radiation therapy and chemoradiation, the fatality rate for esophageal cancer remains high. Specifically, Fusobacterium nucleatum, due to its aggregation capacity, has shown a tendency to form biofilms. The biofilm-forming capabilities of microbial communities are of utmost importance in the context of cancer treatment, as they have been shown to drive significant losses in the efficaciousness of various cancer treatments. Therefore, elucidating the dynamics of F. nucleatum will be important for the development of effective treatments for esophageal cancer. Therefore, this review summarizes the current knowledge of F. nucleatum, its involvement in cancer and its impact on chemotherapy and radiation therapy. In conclusion, further research on the role of F. nucleatum is essential for the continued advancement of the treatment of esophageal cancer and patient care.

查看原文本刊更多论文

核酸分枝杆菌在癌症治疗（包括放射治疗）中的影响及其在食道癌中的未来潜力。

尽管手术、化疗、放疗和化学放疗等多模式疗法取得了进展，但食管癌的死亡率仍然很高。特别是核酸镰刀菌，由于其聚集能力，显示出形成生物膜的倾向。微生物群落的生物膜形成能力对癌症治疗至关重要，因为它们已被证明会导致各种癌症治疗方法的疗效大打折扣。因此，阐明 F. nucleatum 的动态变化对于开发食管癌的有效治疗方法非常重要。因此，本综述总结了目前关于核酸酵母菌的知识、其在癌症中的参与及其对化疗和放疗的影响。总之，进一步研究 F. nucleatum 的作用对于继续推进食管癌治疗和患者护理至关重要。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Radiation Research 医学-核医学

CiteScore

3.60

自引率

5.00%

发文量

审稿时长

4-8 weeks

期刊介绍： The Journal of Radiation Research (JRR) is an official journal of The Japanese Radiation Research Society (JRRS), and the Japanese Society for Radiation Oncology (JASTRO). Since its launch in 1960 as the official journal of the JRRS, the journal has published scientific articles in radiation science in biology, chemistry, physics, epidemiology, and environmental sciences. JRR broadened its scope to include oncology in 2009, when JASTRO partnered with the JRRS to publish the journal. Articles considered fall into two broad categories: Oncology & Medicine - including all aspects of research with patients that impacts on the treatment of cancer using radiation. Papers which cover related radiation therapies, radiation dosimetry, and those describing the basis for treatment methods including techniques, are also welcomed. Clinical case reports are not acceptable. Radiation Research - basic science studies of radiation effects on livings in the area of physics, chemistry, biology, epidemiology and environmental sciences. Please be advised that JRR does not accept any papers of pure physics or chemistry. The journal is bimonthly, and is edited and published by the JRR Editorial Committee.